Recent observations on the interaction of plasma oestrogen levels with the preventive effect of the aromatase inhibitor anastrozole make it timely to consider the development of oestrogen-targeted prevention of breast cancer and the evidence upon which that development was made. The gene discussed is CYP19A1; the disease is breast carcinoma.